News

According to results of an intent-to-treat (ITT) analysis announced by Vertex Pharmaceuticals, more than 80% of hepatitis C patients in each arm of the phase 2 Study C208

Valeant Pharmaceuticals (Valeant) has reported a total revenue of $220.3m for the third quarter of 2009, an increase of 31% compared to $168.4m in the third quarter of

EnzymeRx has launched its first clinical study for Uricase-PEG20. The company said that subjects have begun enrolling in a phase 1 safety, pharmacokinetic and pharmacodynamic study of single

to-BBB has entered into a research collaboration with Genzyme to evaluate to-BBB’s proprietary G-Technology to safely enhance delivery of biologics for neurodegenerative diseases. G-Technology is designed to transport

InteRNA Technologies and the Dana-Farber Cancer Institute have entered into a research agreement to develop microRNA (miRNA)-based therapeutics for cancer. Under the collaboration with William Hahn, associate professor

Quintiles has entered into a clinical pharmacology alliance with AstraZeneca to deliver AstraZeneca’s clinical pharmacology studies across multiple therapy areas around the globe. Quintiles is expected to assume

GlaxoSmithKline (GSK) and Valeant Pharmaceuticals (Valeant) have provided updates on the New Drug Application for retigabine. GSK and Valeant had filed a New Drug Application with the FDA

Amylin Pharmaceuticals (Amylin) and Takeda Pharmaceutical (Takeda) have entered into a worldwide exclusive license, development and commercialisation agreement to co-develop and commercialise pharmaceutical products for the treatment of

Schering-Plough has reported that its investigational sublingual Grass (Phleum Pratense) Allergy Immunotherapy Tablet (AIT) has met the primary endpoint in a phase III study of adult subjects in